SCHEMBL5847255

SCHEMBL5847255

CCCCCCC1C(=O)OC1CCCCCc1ccc(OC(N)=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LYPLA1 O75608 4/20 0.55
LYPLA2 O95372 4/20 0.55
ABHD16A O95870 1/20 0.55
PLA2G6 O60733 2/20 0.55
PLA2G4A P47712 1/20 0.55
PNLIP P16233 4/20 0.48
THRB P10828 2/20 0.47
THRA P10827 1/20 0.47
DAGLA Q9Y4D2 4/20 0.46
PRKCA P17252 3/20 0.44
PRKD3 O94806 1/20 0.44
PRKCG P05129 1/20 0.44
PRKCB P05771 1/20 0.44
PRKCH P24723 1/20 0.44
PRKCE Q02156 1/20 0.44
PRKCQ Q04759 1/20 0.44
PRKCD Q05655 1/20 0.44
PRKD1 Q15139 1/20 0.44
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1840959 0.82 THRB (0.66) THRBTHRA
SCHEMBL1837008 0.82 THRB (0.66) THRBTHRA
SCHEMBL1838051 0.82 THRB (0.66) THRBTHRA
SCHEMBL1951721 0.82 THRB (0.66) THRBTHRA
SCHEMBL1835737 0.82 THRB (0.66) THRBTHRA
SCHEMBL1839479 0.82 THRB (0.66) THRBTHRA
SCHEMBL5847250 0.81 LYPLA1 (0.51) LYPLA1LYPLA2ABHD16APLA2G6PLA2G4A
SCHEMBL1838228 0.80 THRB (0.67) THRBTHRA
SCHEMBL19514898 0.80 PLA2G6 (0.84) LYPLA1LYPLA2ABHD16APLA2G6PLA2G4A
SCHEMBL19514903 0.80 PLA2G6 (0.84) LYPLA1LYPLA2ABHD16APLA2G6PLA2G4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074822-B2 Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2006-07-11 US disclosed
US-20050197386-A1 Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197386-A1 Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them PNLIP, CEL, LIPE LYPLA1 19/4885LYPLA2 28/4885ABHD16A 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.